154 related articles for article (PubMed ID: 21900378)
1. Telomere length and telomerase reverse transcriptase gene copy number in patients with papillary thyroid carcinoma.
Jendrzejewski J; Tomsic J; Lozanski G; Labanowska J; He H; Liyanarachchi S; Nagy R; Ringel MD; Kloos RT; Heerema NA; de la Chapelle A
J Clin Endocrinol Metab; 2011 Nov; 96(11):E1876-80. PubMed ID: 21900378
[TBL] [Abstract][Full Text] [Related]
2. Short telomeres, telomerase reverse transcriptase gene amplification, and increased telomerase activity in the blood of familial papillary thyroid cancer patients.
Capezzone M; Cantara S; Marchisotta S; Filetti S; De Santi MM; Rossi B; Ronga G; Durante C; Pacini F
J Clin Endocrinol Metab; 2008 Oct; 93(10):3950-7. PubMed ID: 18664542
[TBL] [Abstract][Full Text] [Related]
3. Lack of mutations of the telomerase RNA component in familial papillary thyroid cancer with short telomeres.
Cantara S; Capuano S; Capezzone M; Benigni M; Pisu M; Marchisotta S; Pacini F
Thyroid; 2012 Apr; 22(4):363-8. PubMed ID: 22304389
[TBL] [Abstract][Full Text] [Related]
4. Telomere length in neoplastic and nonneoplastic tissues of patients with familial and sporadic papillary thyroid cancer.
Capezzone M; Cantara S; Marchisotta S; Busonero G; Formichi C; Benigni M; Capuano S; Toti P; Pazaitou-Panayiotou K; Caruso G; Carli AF; Palummo N; Pacini F
J Clin Endocrinol Metab; 2011 Nov; 96(11):E1852-6. PubMed ID: 21865371
[TBL] [Abstract][Full Text] [Related]
5. Genetic Heterogeneity of HER2 Amplification and Telomere Shortening in Papillary Thyroid Carcinoma.
Caria P; Cantara S; Frau DV; Pacini F; Vanni R; Dettori T
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775641
[TBL] [Abstract][Full Text] [Related]
6. Telomere abnormalities and chromosome fragility in patients affected by familial papillary thyroid cancer.
Cantara S; Pisu M; Frau DV; Caria P; Dettori T; Capezzone M; Capuano S; Vanni R; Pacini F
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1327-31. PubMed ID: 22539583
[TBL] [Abstract][Full Text] [Related]
7. Telomere length is shorter in affected members of families with familial nonmedullary thyroid cancer.
He M; Bian B; Gesuwan K; Gulati N; Zhang L; Nilubol N; Kebebew E
Thyroid; 2013 Mar; 23(3):301-7. PubMed ID: 23009101
[TBL] [Abstract][Full Text] [Related]
8. In situ detection of hTERT mRNA relates to Ki-67 labeling index in papillary thyroid carcinoma.
Chou SJ; Chen CM; Harn HJ; Chen CJ; Liu YC
J Surg Res; 2001 Jul; 99(1):75-83. PubMed ID: 11421607
[TBL] [Abstract][Full Text] [Related]
9. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
[TBL] [Abstract][Full Text] [Related]
10. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF
Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T
Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
[TBL] [Abstract][Full Text] [Related]
11. The clinicopathologic characteristics of familial and sporadic papillary thyroid carcinoma in Turkish patients.
Sezer H; Demirkol MO; Yazici D; Kapran Y; Alagöl MF
Turk J Med Sci; 2020 Apr; 50(2):360-368. PubMed ID: 31999407
[TBL] [Abstract][Full Text] [Related]
12. Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma.
Wang N; Xu D; Sofiadis A; Höög A; Vukojević V; Bäckdahl M; Zedenius J; Larsson C
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1571-9. PubMed ID: 24758186
[TBL] [Abstract][Full Text] [Related]
13. TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer.
Myung JK; Kwak BK; Lim JA; Lee MC; Kim MJ
Cancer Res Treat; 2016 Jul; 48(3):942-7. PubMed ID: 26727717
[TBL] [Abstract][Full Text] [Related]
14. [Biological characteristics and management of familial papillary thyroid carcinoma].
Zhao J; Yu Y; Xia TT; Liu YZ; Wei SF; Zheng XQ; Gao M
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Nov; 46(11):897-900. PubMed ID: 22335974
[TBL] [Abstract][Full Text] [Related]
15. Thyroid carcinoma-featured telomerase activation and telomere maintenance: Biology and translational/clinical significance.
Yuan X; Yuan H; Zhang N; Liu T; Xu D
Clin Transl Med; 2022 Nov; 12(11):e1111. PubMed ID: 36394204
[TBL] [Abstract][Full Text] [Related]
16. Telomerase activity and telomere length in benign and malignant human thyroid tissues.
Kammori M; Takubo K; Nakamura K; Furugouri E; Endo H; Kanauchi H; Mimura Y; Kaminishi M
Cancer Lett; 2000 Oct; 159(2):175-81. PubMed ID: 10996729
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter hotspot mutations and their relationship with TERT levels and telomere erosion in patients with head and neck squamous cell carcinoma.
Boscolo-Rizzo P; Giunco S; Rampazzo E; Brutti M; Spinato G; Menegaldo A; Stellin M; Mantovani M; Bandolin L; Rossi M; Del Mistro A; Tirelli G; Dei Tos AP; Guerriero A; Niero M; Da Mosto MC; Polesel J; De Rossi A
J Cancer Res Clin Oncol; 2020 Feb; 146(2):381-389. PubMed ID: 31960186
[TBL] [Abstract][Full Text] [Related]
18. Telomere length and TERT abnormalities in pituitary adenomas.
Boresowicz J; Kober P; Rusetska N; Maksymowicz M; Goryca K; Kunicki J; Bonicki W; Bujko M
Neuro Endocrinol Lett; 2018 Mar; 39(1):49-55. PubMed ID: 29803207
[TBL] [Abstract][Full Text] [Related]
19. Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation.
Chien MN; Yang PS; Hsu YC; Liu TP; Lee JJ; Cheng SP
Head Neck; 2018 Nov; 40(11):2528-2537. PubMed ID: 30102829
[TBL] [Abstract][Full Text] [Related]
20. Telomerase reverse transcriptase haploinsufficiency and telomere length in individuals with 5p- syndrome.
Du HY; Idol R; Robledo S; Ivanovich J; An P; Londono-Vallejo A; Wilson DB; Mason PJ; Bessler M
Aging Cell; 2007 Oct; 6(5):689-97. PubMed ID: 17875000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
